Drugs / SF1126
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03059147 | Mar 2017 → Apr 2019 | hepatocellular carcinoma | SignalRX Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02337309 | Jul 2015 → May 2018 | neuroblastoma | New Approaches to Neuroblastoma Therapy Consortium | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00907205 | Apr 2007 → Jan 2011 | cancer | Semafore Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02644122 | Nov → Dec 2016 | metastatic squamous cell carcinoma | Ezra Cohen | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SF1126 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00907205 ↗ |
| Known as | SF-1126 INNER SALT | ChEMBL registry synonym — accepted as the source's own label CHEMBL2326966 ↗ |
| Action | Inhibit | “selectively inhibits all PI3K class I isoforms” NCT00907205 ↗1“Serine/threonine-protein kinase mTOR inhibitor” CHEMBL2326966 ↗ |
| Modality | Peptide | “SF1126 is a peptidic pro-drug inhibitor of pan-PI3K/mTORC.” PMID 22921184 ↗ Aug 2012 |
| Route | Intravenous | “SF1126 was administered IV days 1 and 4, weekly in 28day-cycles.” PMID 22921184 ↗ Aug 2012 |
| Target | BRD4 | “dual inhibitor of phosphatidylinositol-3-kinase (pan-isoform specific) and bromodomain-containing protein 4 (BRD4)” NCT03059147 ↗ |
| Target | MTOR | “Serine/threonine-protein kinase mTOR inhibitor” CHEMBL2326966 ↗ |